TGF-β3 Inhibits Antibody Production by Human B Cells

Yumi Tsuchida¹, Shuji Sumitomo¹, Kazuyoshi Ishigaki¹,², Akari Suzuki², Yuta Kochi², Haruka Tsuchiya¹, Mineto Ota¹, Toshihiko Komai¹, Mariko Inoue¹, Kaoru Morita¹, Tomohisa Okamura¹,³, Kazuhiko Yamamoto¹, Keishi Fujio¹*

¹ Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ² Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ³ Max Planck-The University of Tokyo Center for Integrative Inflammology, The University of Tokyo, Tokyo, Japan

* kfujio-tky@umin.ac.jp

Abstract

TGF-β is a pleotropic cytokine involved in various biological processes. Of the three isoforms of TGF-β, TGF-β1 has long been recognized as an important inhibitory cytokine in the immune system and has been reported to inhibit B cell function in both mice and humans. Recently, it has been suggested that TGF-β3 may play an important role in the regulation of immune system in mice. Murine CD4⁺CD25⁻LAG3⁺ regulatory T cells suppress B cell function through the production of TGF-β3, and it has been reported that TGF-β3 is therapeutic in a mouse model of systemic lupus erythematosus. The effect of TGF-β3 on human B cells has not been reported, and we herein examined the effect of TGF-β3 on human B cells. TGF-β3 suppressed B cell survival, proliferation, differentiation into plasmablasts, and antibody secretion. Although the suppression of human B cells by TGF-β1 has long been recognized, the precise mechanism for the suppression of B cell function by TGF-β1 remains elusive; therefore, we examined the effect of TGF-β1 and β3 on pathways important in B cell activation and differentiation. TGF-β1 and TGF-β3 inhibited some of the key molecules of the cell cycle, as well as transcription factors important in B cell differentiation into antibody secreting cells such as IRF4, Blimp-1, and XBP1. TGF-β1 and β3 also inhibited B cell receptor signaling. Our results suggest that TGF-β3 modifying therapy might be therapeutic in autoimmune diseases with B cell dysregulation in humans.

Introduction

Transforming growth factor-beta (TGF-β) is a pleotropic cytokine involved in various biological processes. There are three isoforms of TGF-β in mammals[1]. Each isoform is thought to have different biological roles in vivo as the expression of the three isoforms differ in their pattern of expression and knock out mice of different isoforms exhibit different phenotypes[2, 3]. TGF-β1 knock out mice develop autoimmune disease characterized by inflammation in various organs and production of autoantibodies[4, 5]. TGF-β2 knockout mice exhibit various congenital abnormalities involving the cardiovascular, pulmonary, skeletal, and urogenital
data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** KY received financial support or fees from AbbVie, Astellas, BMS, Daiichi-Sankyo, Mitsubishi Tanabe, Pfizer, Santen, Takeda, Teijin, Boehringer Ingelheim, Chugai, Eisai, Ono, Taisho Toyama, UCB, ImmunoFuture, Asahi Kasei, and Janssen. KF received financial support or fees from Astellas, BMS, Daiichi-Sankyo, Mitsubishi Tanabe, Pfizer, Santen, Takeda, Teijin, Boehringer Ingelheim, Chugai, Eisai, Taisho Toyama and UCB and Janssen. The other authors declare no competing financial interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials. However, TGF-β1, when present with inflammatory cytokines, may promote inflammation by promoting the differentiation of Th17 cells[9].

TGF-β1 has profound effects on B cells as well and has been reported to inhibit proliferation and antibody production of B cells in both mice and humans[10–13]. However, in certain contexts, TGF-β1 induces proliferation of B cells and IgA production[12, 14–16]. In vivo, TGF-β1 is expressed on the surface of Foxp3+ Treg cells and is involved in the inhibition of B cells by Foxp3+ Treg cells[17]. However, studies of the mechanism of B cell inhibition by TGF-β1 on human B cells have mainly been conducted in the context of oncology using cell lines with a focus on oncogenes and apoptosis related genes[18–22]. Thus, our knowledge of the effect of TGF-β1 on signal pathways in primary human B cells, especially on pathways important in antibody production, is limited.

Until recently, the role of TGF-β3 in vivo has mainly been described in development with little focus on the immune system[1], but there is emerging evidence from studies in mice that TGF-β3 is also important in the regulation of the immune system. For instance, Th17 cells induced in the presence of TGF-β3 exhibit different characteristics from Th17 cells induced in the presence of TGF-β1[23]. In addition, TGF-β3 produced by resting B cells induce proliferation of Foxp3− Treg cells[24]. TGF-β3 is also produced by CD4+CD25 LAG3+ Treg cells, IL-10 producing Treg cells characterized by the expression of early growth response protein-2 and lymphocyte activation gene 3 (LAG3) protein[25, 26]. LAG3+ Treg cells suppress B cells through the production of TGF-β3[25]. The administration of TGF-β3 expressing vector to MRL/lpr mouse, a mouse model of systemic lupus erythematosus (SLE), ameliorated the progression of nephritis. Thus, TGF-β3 modifying therapy might be therapeutic in autoimmune diseases with B cell dysregulation[25].

We herein examined the effect of TGF-β3 on human B cells, which has not yet been reported. Like TGF-β1, TGF-β3 suppressed B cell survival, proliferation, differentiation into antibody-secreting cells (ASCs), and antibody production. To elucidate the mechanism for inhibition of human primary B cells by TGF-β1 and β3, we performed transcriptome analysis using RNA-Sequencing (RNA-Seq) and subsequent pathway analysis, followed by further analysis of some of the key molecules.

**Materials and Methods**

**Cell Isolation and Culture**

Peripheral blood mononuclear cells (PBMCs) were separated from heparinized whole blood by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare). B cells were purified using Human B Cell Isolation Kit II (Miltenyi Biotec), and naïve B cells were isolated using Human Naïve B Cell Isolation Kit (Miltenyi Biotec). The ethics committee of the University of Tokyo Hospital approved this study (No. 10154 and G3582). All subjects provided written informed consent, and the study was conducted in accordance with relevant guidelines.
Unless otherwise indicated, cells were cultured in RPMI 1640 (Invitrogen) supplemented with 10% FCS (Equitech Bio), 100 μg/ml L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin (Invitrogen), and 50 μM 2-ME (Sigma). In some experiments, cells were cultured in X-VIVO15 (Lonza) to exclude the effect of TGF-β in FCS.

TGF-β1 and β3 (R&D) were used at 1 ng/ml unless otherwise indicated. IL-21 (PeproTech), IL-4 (R&D), soluble CD40L (PeproTech), and CpG-ODN2006 (Enzo Life Sciences) were used at 50 ng/ml, 100U/ml, 2 μg/ml, and 6 μg/ml respectively, and BCR stimulation was induced using goat anti-human IgA + IgG + IgM (H+L) (Jackson Immunoresearch) at 2.5 μg/ml.

**Antibody Production**

B cells and PBMCs were cultured at 3x10^5/well in 96 well plates. ELISA was performed using Human IgG ELISA Quantitation Set, Human IgA ELISA Quantitation Set, and Human IgM ELISA Quantitation Set (Bethyl Laboratories).

**Assessment of Cell Proliferation**

Cells were suspended in 2% FCS-containing medium at 1 x 10^7/ml, and CFSE (Dojindo) was added to achieve a final concentration of 2 μM. After incubating for 5 minutes at room temperature, cells were washed with 100% FCS and cultured in 10% FCS-containing medium.

**Flow Cytometry**

Human Fc Receptor Binding Inhibitor Purified (eBioscience) was used to block unspecific Ab binding, and the cells were stained with the following monoclonal Abs: APCCy7-CD19 (HIB19, BioLegend), APC-CD38 (HIT2, Biolegend), and PECy7-CD38 (HIT2, Biolegend). For the quantification of light chains on the cell surface, mouse anti-human Ig κ light chain (G20-193, BD), mouse anti-human Ig λ light chain (JDC-12, BD), and APC rat anti-mouse IgG1 (A85-1, BD) were used. 7-Amino-Actinomycin D (Biologend) was used to assess cell death. For intracellular staining of Blimp-1, Blimp-1 (N-20) AF488 (Santa Cruz) and Foxp3/Transcription Factor Staining Buffer Set (eBioscience) were used. For intracellular staining of phosphorylated STAT3, cells were fixed with 2% paraformaldehyde, permeabilized with 96% methanol, and stained with PE Mouse Anti-Stat3 (pY705, BD). Flow cytometry was performed using MoFlo XDP (Beckman Coulter), and data were analyzed using FlowJo 7.6.5 (Tree Star).

**RNA-Seq**

RNA was extracted using RNasy Micro Kit (Qiagen), and libraries were prepared using TruSeq Stranded mRNA LT Kit (Illumina). Paired-end sequencing was performed using HiSeq 2500 (Illumina). Cutadapt[27] and FASTX-Toolkit (http://hannonlab.cshl.edu/fastx-toolkit) were used to remove adaptor sequences and ends with phred quality scores less than 20. UCSC hg19 reference sequence (http://genome.ucsc.edu/) was used as the reference genome, and STAR[28] was used for mapping. Read count was obtained for each gene using HTSeq[29]. Read count after quality control was 4.9x10^6 ~ 9.7x10^6. Differential gene analysis was performed using edgeR 3.12.0[30]. Pathway analysis was performed by uploading genes with false discovery rate less than 0.05 by the Benjamini-Hochberg method and their logFCs into IPA software (Qiagen)[31]. R version 3.2.3 was used for RNA-Seq analysis.

**Quantitative PCR**

RNasy Micro Kit (Qiagen) was used to extract RNA, and cDNA was synthesized using Random Primers (Invitrogen) and Superscript III (Invitrogen). Quantitative PCR was performed
using QuantiTect SYBR Green PCR Kit (Qiagen) and CFX Connect Realtime PCR (BioRad).

Primers used were as follows: GAPDH (Forward: GAAGTGCAAGTTGAGTAGT, Reverse: GAAATGGTGATGGGATTTCC), IRF4 (Forward: ACCTGCAAATCTTTGACAC, Reverse: AAAGCATAAGTGGTGATGGGATTTC), PRDM1 (Forward: GTGCCAGACCTCAGACTACG, Reverse: TTGCCCAACCAGGATATCAGACT), BCL6 (Forward: GTGGCTTTTGAGGAAAT, Reverse: AACCTGAAAACCCACACTCG), PAX5 (Forward: ATCATCCGGACAAAAGTACAGC, Reverse: GTGCTCACCGAGGACAC), FCRL4 (Forward: GTGAGGGGTAACATCCACAAGC, Reverse: CTTCAGCCACGGAGCAGAC), and AICDA (Forward: GACTTTGGTTATCTTCGCAATAAGA, Reverse: AGGTCCCAGTCCGAGATGTA).

For the quantification of mature Ig transcripts framework 3 (FR3) forward primer (GAACGGTGTTACTTTGGCTG) was used in combination with the following reverse primers: VHDJ1-Cα1 (GTTTTGTCACAAGATTTGGGCTC), VHDJ1-Cα2 (GTGGGCACTCGACACAACCTTGCG), VHDJ1-Cα3 (TTGTGTCACCAAGTGGGGTTTGAGC), and VHDJ1-Cα4 (TGTTGGCGGTTAGTGGGGTTGCTAGCA)[32]. Expression relative to GAPDH was calculated using the comparative Ct method.

Western Blotting

Cells were lysed using lysis buffer (50mM Tris HCl pH 7.5, 150mM NaCl, 1% Triton X-100, 1mM EDTA) and denatured with Laemmli Sample Buffer (Biorad) at 95˚C for 5 minutes. After SDS-PAGE, proteins were transferred to Immobilon-P Transfer Membrane (Millipore). After blocking with 5% BSA or 5% skim milk, blots were incubated overnight with following primary Abs: phospho-Smad1/5, phospho-Smad2, phospho-Smad3, phospho-Syk, total Syk, phospho-NF-κB p65, total NF-κB (all from Cell Signaling), or Actin (I-19) (SantaCruz). The blots were then incubated with HRP-Goat Anti-Rabbit IgG (H+L) (Zymed or Invitrogen), and bands were detected using ECL Select Western Blotting Detection Reagent (GE Healthcare). Stripping was performed with Restore PLUS Western Blot Stripping Buffer (Thermo Scientific) or buffer prepared in-house (50 mM 2-ME, 2% SDS, 100 mM Tris-HCl).

Statistical Analysis

Data are presented as average ± SD. With the exception of RNA-Seq data, data were analyzed using GraphPad Prism 5 (GraphPad Software). For comparison of multiple groups, one way ANOVA and Dunnett test were used. p-values less than 0.05 were considered significant. * and ** indicate p<0.05, p<0.01, p<0.001, and p<0.0001 respectively.

Results

TGF-β3 Inhibits Antibody Production by Human B Cells

TGF-β3 inhibited IgG, IgA, and IgM production by human B cells under IL-21 and CD40L stimulation as strongly as TGF-β1 (Fig 1A). Although the majority is in the latent form and not biologically active, FCS has been reported to contain 1–2 ng/ml of TGF-β1[33], and to exclude the effect of TGF-β1 in the FCS, the experiment was conducted in serum free medium with similar results (Fig 1B). TGF-β1 and TGF-β3 induced cell death in human B cells, suggesting that the decrease in antibody production may partly be due to decreased survival of B cells (Fig 1C). In addition, B cell proliferation and differentiation into CD38high plasmablasts were inhibited by TGF-β1 and TGF-β3; therefore, in addition to decreased cell survival, the decrease in antibody production by TGF-β1 and β3 may be due to decreased cell proliferation and differentiation into ASCs (Fig 1D). To assess the effect of TGF-β1 and β3 in a more physiological condition with help from T cells, B cells were cultured along with autologous PBMCs. TGF-β1
and β3 also inhibited IgG production under this condition (Fig 1E). The expression of mature IgG1, IgG2, IgG3, IgA1, and IgA2 transcripts, as well as AICDA, were downregulated by TGF-β1 and β3, suggesting that TGF-β1 and β3 suppress class switching and affinity maturation (Fig 2).
In addition to interleukins and CD40L, Toll-like receptor (TLR) stimulation and B cell receptor (BCR) stimulation also play important roles in activating B cells; therefore, the effect of TGF-β1 and β3 was assessed in B cells cultured under TLR9 stimulation and BCR stimulation. Antibody production and B cell proliferation were inhibited by TGF-β1 and β3 in B cells cultured under TLR9 stimulation (Fig 3A and 3B), and TGF-β1 and β3 inhibited B cell proliferation and differentiation into CD38\textsuperscript{high} plasmablasts when B cells were stimulated with BCR agonists along with other stimulatory signals (Fig 3C and 3D).

**TGF-β3 Induces Phosphorylation of Smad1/5**

Next, we sought to determine signal transduction pathways involved in B cell suppression by TGF-β3. The canonical pathway for signal transduction of the TGF-β superfamily is the Smad pathway. In general, TGF-β signals through Smad2 and Smad3, and Smad1 and Smad5 are involved in the transduction pathway of other members of the TGF-β superfamily, such as bone morphogenetic proteins (BMPs). However, it has been suggested that phosphorylation of Smad1 and Smad5 may be important for the suppression of human B cells by TGF-β1, and it has also been reported that Smad1/5 are phosphorylated upon TGF-β1 stimulation in human primary B cells.

Therefore, we examined whether TGF-β3 induces phosphorylation of Smad1 and Smad5 as well. B cells were cultured overnight in serum free medium to exclude the effect of TGF-β in the serum and stimulated for an hour with TGF-β1 or β3. Like TGF-β1, TGF-β3 induced...
phosphorylation of Smad1 and Smad5 in primary human B cells (Fig 4A) in addition to Smad2 and Smad3 (Fig 4B).

Fig 3. TGF-β1 and β3 inhibit B cell function under various stimulatory conditions. (a) B cells were stimulated with CpG-ODN2006 for 8 days, and antibody production was assessed by ELISA. Among the CpG-ODN2006 stimulated samples, each of the TGF-β treated samples was compared with TGF-β untreated sample using one way ANOVA, Dunnett test (n = 3). Results are representative of two independent experiments. (b) B cells were stimulated with CpG-ODN2006 for 6 days, and proliferation of CD19⁺7AAD⁻ cells was assessed by flow cytometry. Among the CpG-ODN2006 stimulated samples, TGF-β treated cells were compared with TGF-β untreated cells using one way ANOVA, Dunnett test (n = 3). Results are representative of two independent experiments. (c) B cells were cultured under IL-21, sCD40L, CpG-ODN2006, and BCR stimulation for 4 days, and proliferation of CD19⁺7AAD⁻ cells was assessed by flow cytometry. Among the stimulated samples, TGF-β treated cells were compared with TGF-β untreated cells using one way ANOVA, Dunnett test (n = 3). Results are representative of two similar experiments. (d) B cells were cultured under CpG-ODN2006 and BCR stimulation for 6 days, and the percentage of CD38⁺ plasmablasts among CD19⁺ B cells was assessed by flow cytometry. TGF-β treated cells were compared with TGF-β untreated cells using one way ANOVA, Dunnett test (n = 3). Results are representative of two similar experiments.

doi:10.1371/journal.pone.0169646.g003
TGF-β1 and β3 Inhibit Various Molecules Important for B Cell Function

To further elucidate the mechanism for B cell suppression by TGF-β1 and β3, B cells from healthy individuals were cultured under IL-21 and CD40L stimulation with or without TGF-β1 and β3, and transcriptome analysis was performed by RNA-Seq. Both TGF-β1 and β3 induced profound changes in the transcriptome, and the changes induced by TGF-β1 and β3 were similar with the majority of genes differentially expressed by TGF-β1 having a tendency to be modulated in the same direction by TGF-β3 (Fig 5A).

Consistent with the inhibition of B cell proliferation by TGF-β3, TGF-β3 downregulated key molecules involved in the cell cycle such as E2F proteins, cyclin dependent kinase 1 (CDK1), and cyclin D2 (CCND2) (Fig 5B), and pathway analysis using IPA suggested that “proliferation of cells” and related pathways were suppressed by TGF-β3 (Table 1). TGF-β3 downregulated Src family kinases that are important in B cell proliferation, including Hck and Fgr[34]. NFKBIA, which encodes IkBα and inhibits NF-κB signaling, was induced by TGF-β3. Other negative regulators of B cell activation and survival, including S1PR2[35], DUSP4[36], FCRL4[37], and STK17A[38, 39], were also induced by TGF-β3 (Fig 5B).

Further examination of genes important in B cell function showed that transcription factors (TFs) important in B cell differentiation into ASCs, including interferon regulatory factor 4 (IRF4), PRDM1, and X-box binding protein 1 (XBP1), were downregulated by both TGF-β1 and β3 (Fig 5C). In addition, TGF-β1 and β3 tended to suppress the expression of certain co-stimulatory molecules, pro-inflammatory cytokines, and chemokines, suggesting that TGF-β1 and β3 may inhibit B cell function as APCs and producers of pro-inflammatory cytokines and chemokines in addition to their role as ASCs (Fig 5C). Next, Ingenuity Pathway Analysis (IPA) was used to predict “upstream regulators” that could explain changes in the transcriptome induced by TGF-β3, and molecules important in B cell proliferation and differentiation, including FOXM1[40] and cRel[41], were predicted to be suppressed by TGF-β3 (Table 2).

TGF-β1 and β3 Inhibit TFs Essential for B Cell Differentiation into ASCs

In B cells, high levels of IRF4 induce the expression of B lymphocyte-induced maturation protein-1 (Blimp-1), and Blimp-1, in turn, induces various TFs essential for ASCs, such as XBP1[42]. As TGF-β1 and β3 suppress B cell differentiation into ASCs (Figs 1C and 3D) and RNA-Seq analysis suggested that TGF-β3 suppresses the expression of those TFs (Fig 5C), the effect of TGF-β1 and β3 on those TFs was examined further. Quantitative PCR confirmed that both TGF-β1 and β3 inhibit the expression of IRF4, PRDM1, and XBP1, and B cells treated with TGF-β1 or β3 failed to downregulate BCL6 and PAX5, TFs that suppress differentiation into ASCs.
ASCs (Fig 6A–6D). Intracellular staining indicated that both TGF-β1 and β3 inhibit the expression of Blimp-1 at the protein level as well (Fig 6E).

**TGF-β1 and β3 Inhibit Phosphorylation of Syk**

TGF-β3 has been reported to suppress phosphorylation of Syk, RelA, and STAT proteins in mice[25]. To further elucidate the mechanism for the inhibition of B cell function by TGF-β1 and β3 in humans, the effect of TGF-β1 and β3 on phosphorylation of Syk, RelA, and STAT3 was examined. B cells treated overnight with TGF-β1 and β3 showed decreased phosphorylation of Syk upon B cell receptor (BCR) stimulation (Fig 7A). However, phosphorylation of RelA was not inhibited by TGF-β1 or TGF-β3 in humans (Fig 7B). TGF-β1 and β3 did not substantially affect phosphorylation of STAT3 upon IL-21 stimulation either (Fig 7C).

To examine the mechanism for the inhibition of Syk phosphorylation by TGF-β1 and β3, the expression of the λ light chain and the κ light chain on the cell surface was examined on B cells cultured with TGF-β1 and β3. The expression of the λ light chain and the κ light chain did not change to a significant extent upon overnight culture with TGF-β1 or β3 (S1 Fig), suggesting that the decrease in phosphorylation of Syk was not due to reduced expression of the BCR complex on the cell surface. Fc receptor like 4 (FcRL4) has been reported to inhibit phosphorylation of Syk upon BCR stimulation by interacting with phosphatases, SHP-1 and SHP-2 [37]. As FcRL4 has been implicated in TGF-β1 mediated suppression of B cell function in HIV infection[43] and RNA-Seq analysis suggested that TGF-β3 also induces the expression of FcRL4 (Fig 5B), we hypothesized that FcRL4 might also be involved in the inhibition of Syk phosphorylation by TGF-β3. Quantitative PCR confirmed that B cells cultured overnight with TGF-β1 and β3 upregulated FcRL4, suggesting that TGF-β1 and β3 may inhibit phosphorylation of Syk by upregulating FcRL4 (Fig 7D).

**Discussion**

TGF-β3 is a cytokine whose importance has recently been recognized in immunology[23–25, 44] and inhibits the function of murine B cells[25]. The effect of TGF-β3 on human B cells has not yet been reported, and we herein examined the effect of TGF-β3 on human B cells.

| Diseases or Functions Annotation                  | p-Value        | Activation z-score |
|--------------------------------------------------|----------------|--------------------|
| cell proliferation of tumor cell lines           | $1.12 \times 10^{-21}$ | -4.04              |
| proliferation of cells                           | $8.90 \times 10^{-43}$ | -3.66              |
| cell proliferation of breast cancer cell lines   | $5.79 \times 10^{-11}$ | -3.29              |
| metabolism of DNA                                | $1.35 \times 10^{-9}$  | -3.07              |
| M phase of tumor cell lines                      | $1.46 \times 10^{-10}$ | -2.92              |

IPA was used to predict diseases or functions inhibited by TGF-β3. p-Values indicated the degree of overlap between differentially expressed genes between TGF-β untreated and TGF-β3 treated samples and genes in the gene set by Fisher’s exact test, and z-scores are indicators of the activation or inhibition based on the Downstream Effects Analysis algorithm[31]. Five functions with the lowest activation z-scores are shown.
Notably, TGF-β3 inhibited B cell function as potently as TGF-β1. TGF-β3, like TGF-β1, induced phosphorylation of Smad1/5 in addition to Smad2 and Smad3. Transcriptome analysis and subsequent studies revealed that TGF-β1 and β3 suppress key molecules in B cell function such as IRF4, Blimp-1, XBP1, and Syk.

Interestingly, Smad1/5, which are usually known as mediators of BMPs signaling, not TGF-β signaling[1], was phosphorylated upon TGF-β1 and β3 stimulation in human primary B cells in addition to Smad2 and Smad3. Studies of B cell-specific Smad2 deficient mice[45] and Smad3 deficient mice[46] have suggested that Smad2 and Smad3 are not necessary for the inhibition of B cell proliferation by TGF-β1. Among human B cell lymphoma cell lines, TGF-β1 mediated suppression of cell proliferation is seen only in cell lines in which Smad 1/5 are phosphorylated upon TGF-β1 treatment[18]. These studies suggest that Smad1/5 might be important for TGF-β1 mediated suppression of B cells, and our data that TGF-β3 induces Smad1/5 phosphorylation is in line with these reports and also suggests the possibility that Smad1/5 might be involved in the inhibition of B cell function by TGF-β1 and β3.

In murine B cells, it has been reported that Id3, which is induced by Smad1/5, induces growth arrest and apoptosis by antagonizing E proteins[47, 48], and the induction of Id3 by Smad1/5 may also be responsible for the inhibition of human B cells by TGF-β1 and β3. Although it has been reported that Smad signaling and signals further downstream differs between TGF-β1 and β3 in murine T cells[23], in human B cells, phosphorylation of Smad and changes in the transcriptome induced by TGF-β1 and β3 were similar.

It has been reported that the proliferation of B cells is essential for B cell differentiation into ASCs[49, 50], and both TGF-β1 and β3 strongly inhibited B cell proliferation and subsequently differentiation into CD38^high plasmablasts, as well as the expression of key TFs in the differentiation of ASCs, including IRF4, Blimp-1, and XBP1. It has been reported that NFXβ plays an important role in the induction of IRF4 in B cells[51] and as RNA-Seq analysis suggested that TGF-β3 induces the expression of IκBα, the suppression of NFκB signaling by IκBα may play a role in the inhibition of B cell differentiation into ASCs by TGF-β1 and β3.

In addition to IRF4, Blimp-1, and XBP1, phosphorylation of Syk was inhibited by TGF-β1 and β3. FcRL4, which inhibits BCR signaling[37] and has been suggested to mediate B cell inhibition by TGF-β1[43], was also upregulated by TGF-β3; therefore, FcRL4 might be involved in the inhibition of BCR signaling by TGF-β3 as well. Further studies are necessary to determine the exact mechanism for the suppression of BCR signaling by TGF-β1 and β3 and its relationship to Smad signaling.

In general, the effect of TGF-β1 and β3 on human B cells was similar to those reported for murine B cells; however, there were significant differences. For example, in murine B cells, TGF-β3 has been reported to inhibit phosphorylation of RelA[25], but in human B cells, TGF-β3
β1 and β3 did not inhibit phosphorylation of RelA. There may be other differences in the mechanism of B cell suppression by TGF-β1 and β3 between murine and human B cells, and the mechanism for the suppression of human B cells by TGF-β1 and β3 needs to be investigated further. In addition, it has been reported that TGF-β1 enhances B cell proliferation and IgA secretion under certain circumstances [15], and the effect of TGF-β3 on human B cells under those conditions needs further investigation.

Fig 6. TGF-β1 and β3 inhibit TFs essential for B cell differentiation into ASCs. (a-d) B cells were cultured under IL-21 and CD40L stimulation for 3 days (a, b) or 5 days (c, d), and the expression of the indicated genes was assessed by quantitative PCR. Expression relative to GAPDH is shown. TGF-β treated cells were compared with TGF-β untreated cells using one way ANOVA, Dunnett test (n = 5). Results are representative of two (b), three (d), or four (a, c) independent experiments. (e) B cells were cultured under IL-21, CD40L, and CpG-ODN2006 stimulation for 4 days with or without TGF-β. Expression of Blimp-1 on CD19+ B cells was assessed by intracellular staining. TGF-β treated cells were compared with TGF-β untreated cells using one way ANOVA, Dunnett test (n = 3). Results are representative of three similar experiments.

doi:10.1371/journal.pone.0169646.g006
In summary, TGF-β3 suppresses human B cell function as potently as TGF-β1 by suppressing key molecules in B cell function including Syk, IRF4, Blimp-1, and XBP1. TGF-β3 has been suggested to be therapeutic in a mouse model of SLE[25], and the findings of this study suggest that TGF-β3 modifying therapy may be therapeutic in human autoimmune diseases with B cell dysregulation. It has been suggested that B cells with increased Syk phosphorylation might be a source for pathogenic plasma cells in SLE[52], and TGF-β3, which inhibits phosphorylation of Syk and ASC differentiation, may be able to inhibit those B cells as well as their differentiation into pathogenic plasma cells.

The effects of TGF-β1 and β3 on other cell types are different, and TGF-β3 modifying therapy may be more suitable for treatment of autoimmune diseases compared to TGF-β1 for several reasons. First, it has been suggested that TGF-β3 has a better effect on glucose tolerance compared to TGF-β1[53]. In addition, TGF-β1 is associated with cutaneous wound healing with scarring while TGF-β3 is associated with wound healing without scarring[6, 8], and TGF-β1 promotes fibrosis in the lung while TGF-β3 does not[7]. Therefore, an augmentation of TGF-β3 activity could be a potential therapeutic strategy for autoimmune diseases while avoiding glucose intolerance and scarring and fibrosis of other tissues, which might be induced by TGF-β1 modifying therapy. Thus, our study suggests TGF-β3 as a potential new target for therapy in autoimmune diseases.

Supporting Information

S1 Fig. TGF-β1 and β3 do not alter the expression of light chains on the cell surface. B cells were cultured overnight with or without TGF-β, and the expression of the λ light chain and the κ light chain was examined by flowcytometry. Results are representative of two similar
Acknowledgments
The authors would like to thank G Inoue, E Kanno, K Sakashita, and J Takezawa for their excellent technical assistance.

Author Contributions
Conceptualization: YT SS KF.
Formal analysis: YT KI AS YK.
Funding acquisition: SS KY KF.
Investigation: YT SS HT MO TK MI KM.
Resources: KI AS YK.
Supervision: TO KY KF.
Writing – original draft: YT SS.
Writing – review & editing: KF.

References
1. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-beta—an excellent servant but a bad master. J Transl Med. 2012; 10:183. doi:10.1186/1479-5876-10-183 PMID: 22943793
2. Pelton RW, Dickinson ME, Moses HL, Hogan BL. In situ hybridization analysis of TGF beta 3 RNA expression during mouse development: comparative studies with TGF beta 1 and beta 2. Development. 1990; 110:609–20. PMID: 1723948
3. Dunker N, Kriegelstein K. Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis. Eur J Biochem. 2000; 267:6982–8. PMID: 11106407
4. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992; 359:693–9. doi:10.1038/359693a0 PMID: 1436033
5. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandez G, et al. SLE-like autoantibodies and Sjogren’s syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol. 1995; 155:3205–12. PMID: 7673733
6. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995; 108 (Pt 3):985–1002.
7. Ask K, Bonniaud P, Maass K, Eickelberg O, Margetts PJ, Warburton D, et al. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol. 2008; 40:484–95. doi:10.1016/j.biocel.2007.08.016 PMID: 17931953
8. Finnson KW, McLean S, Di Guglielmo GM, Philip A. Dynamics of Transforming Growth Factor Beta Signaling in Wound Healing and Scarring. Adv Wound Care (New Rochelle). 2013; 2:195–214.
9. Banchereau J, Pascual V, O’Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012; 13:325–31. doi:10.1038/ni.2406 PMID: 22990890
10. Kehrl JH, Taylor AS, Delsing GA, Roberts AB, Sporn MB, Fauci AS. Further studies of the role of transforming growth factor-beta in human B cell function. J Immunol. 1998; 143:1868–74. PMID: 2550546
11. Kehrl JH, Thevenin C, Rieckmann P, Fauci AS. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J Immunol. 1991; 146:4016–23. PMID: 1903417
12. Sonoda E, Matsumoto R, Hitoshi Y, Sugimoto M, Araki S, et al. Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med. 1989; 170:1415–20. PMID: 2677210

13. Bouchard C, Fridman WH, Sautes C. Effect of TGF-beta1 on cell cycle regulatory proteins in LPS-stimulated normal mouse B lymphocytes. J Immunol. 1997; 159:4155–64. PMID: 9379008

14. Coffman RL, Lebman DA, Shrader B. Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med. 1989; 170:1039–44. PMID: 2788703

15. Dullaers M, Li D, Xue Y, Ni L, Gayet I, Morita R, et al. A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity. 2009; 30:120–9. doi: 10.1016/j.immuni.2008.11.008 PMID: 19144318

16. van Vlasselaer P, Punnonen J, de Vries JE. Transforming growth factor-beta directs IgA switching in human B cells. J Immunol. 1992; 148:2062–7. PMID: 1347548

17. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001; 194:629–44. PMID: 11535631

18. Bakkebo M, Huse K, Hilden VI, Smeland EB, Oksvold MP. TGF-beta-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK. BMC Immunol. 2010; 11:57. doi: 10.1186/1471-2172-11-57 PMID: 21092277

19. Spender LC, Carter MJ, O'Brien DI, Clark LJ, Yu J, Michalak EM, et al. Transforming growth factor-beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med. 1989; 170:1039–44. PMID: 2788703
34. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbri D, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004; 36:453–61. doi: 10.1038/ng1343 PMID: 15098032
35. Green JA, Cyster JG. S1PR2 links germinal center confinement and growth regulation. Immunol Rev. 2012; 247:36–51. doi: 10.1111/j.1600-065X.2012.01114.x PMID: 22500830
36. Schmid CA, Robinson MD, Scheifinger NA, Muller S, Cogliatti S, Tzankov A, et al. DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. J Exp Med. 2015; 212:775–92. doi: 10.1084/jem.20141957 PMID: 25847947
37. Sohn HW, Krueger PD, Davis RS, Pierce SK. FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling. Blood. 2011; 118:6332–41. doi: 10.1182/blood-2011-05-353102 PMID: 21908428
38. Lawrie CH, Shilling R, Troussard X, Cattan H, Mossafa H, Pezzella F, et al. Expression profiling of persistent polyclonal B-cell lymphocytosis suggests constitutive expression of the AP-1 transcription complex and downregulation of Fas-apoptotic and TGFbeta signalling pathways. Leukemia. 2009; 23:581–3. doi: 10.1038/leu.2008.223 PMID: 18754033
39. Capra M, Nuciforo PG, Confalonieri S, Quarto M, Bianchi M, Nebuloni M, et al. Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res. 2006; 66:8147–54. doi: 10.1158/0008-5472.CAN-05-3489 PMID: 16912193
40. Lefebvre C, Rajbhandari P, Alvarez MJ, Bandaru P, Lim WK, Sato M, et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol. 2010; 6:377. doi: 10.1038/msb.2010.31 PMID: 20531406
41. Grumont RJ, Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med. 2000; 191:1281–92. PMID: 10770796
42. Nett SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015; 15:160–71. doi: 10.1038/nri3795 PMID: 25698678
43. Jelicic K, Cimbro R, Nawaz F, Huang da W, Zheng X, Yang J, et al. The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-beta1 production and FcRL4 expression. Nat Immunol. 2014; 15:1286–95. doi: 10.1038/ni.2993 PMID: 24162774
44. Chikuma S, Suita N, Okazaki IM, Shibayama S, Honjo T. TRIM28 prevents autoinflammatory T cell development in vivo. Nat Immunol. 2012; 13:596–603. doi: 10.1038/ni.2293 PMID: 22544392
45. Klein J, Ju W, Heyer J, Wittek B, Haneke T, Knaus P, et al. B cell-specific deficiency for Smad2 in vivo leads to defects in TGF-beta-directed IgA switching and changes in B cell fate. J Immunol. 2006; 176:2389–96. PMID: 16455997
46. Yang X, Letterio JJ, Grumont R, Grossmann M, Nakamura Y, Pohl T, Nesic D, et al. Rel/NF-kappaB transcription factors: key mediators of B-cell activation. Immunol Rev. 2000; 176:105–13. PMID: 11043773
47. Caron G, Hussain M, Kulis M, Delaloye C, Chatonnet F, Pignarre A, et al. Cell-Cycle-Dependent Reconfiguration of the DNA Methylation during Terminal Differentiation of Human B Cells into Plasma Cells. Cell Rep. 2015; 15:1059–71. doi: 10.1016/j.celrep.2015.09.051 PMID: 26565917
48. Tangye SG, Avery DT, Hodgkin PD. A division-linked mechanism for the rapid generation of Ig-secreting cells from human memory B cells. J Immunol. 2003; 170:261–9. PMID: 12496408
49. Gugasyan R, Grumont R, Grossmann M, Nakamura Y, Pohl T, Nesic D, et al. Rel/NF-kappaB transcription factors: key mediators of B-cell activation. Immunol Rev. 2000; 176:134–40. PMID: 11043773
50. Fleischer SJ, Giesecke C, Mei HE, Lipsky PE, Daridon C, Dormer T. Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic iupus erythematosus. Arthritis Rheumatol. 2014; 66:3424–35. doi: 10.1002/art.38854 PMID: 25156507
51. Hall BE, Wankhade UD, Konkel JE, Cherukuri K, Nagineni CN, Flanders KC, et al. Transforming growth factor-beta3 (TGF-beta3) knock-in ameliorates inflammation due to TGF-beta1 deficiency while promoting glucose tolerance. J Biol Chem. 2013; 288:32074–92. doi: 10.1074/jbc.M113.480764 PMID: 24056369